IQVIA (NYSE:IQV) Cut to Hold at StockNews.com

StockNews.com cut shares of IQVIA (NYSE:IQV) from a buy rating to a hold rating in a report issued on Wednesday.

Several other equities analysts also recently commented on IQV. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Citigroup dropped their price target on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Truist Financial reissued a “buy” rating and issued a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. UBS Group lowered their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, Leerink Partners reiterated an “outperform” rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Stock Performance

Shares of IQVIA stock opened at $185.40 on Wednesday. The company has a market cap of $32.69 billion, a PE ratio of 24.72, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a 50 day moving average of $196.63 and a 200-day moving average of $210.95. IQVIA has a 1-year low of $179.28 and a 1-year high of $256.34.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, equities research analysts forecast that IQVIA will post 10.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On IQVIA

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Synergy Asset Management LLC bought a new stake in IQVIA in the fourth quarter valued at $33,000. Avior Wealth Management LLC increased its position in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after acquiring an additional 87 shares in the last quarter. GKV Capital Management Co. Inc. bought a new stake in shares of IQVIA during the fourth quarter worth about $39,000. Lee Danner & Bass Inc. bought a new stake in shares of IQVIA during the fourth quarter worth about $44,000. Finally, Zions Bancorporation N.A. increased its position in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after acquiring an additional 85 shares in the last quarter. 89.62% of the stock is owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.